PINK1 and Parkinson disease: This approach was taken in the design of a recent trial of coenzyme Q10 supplementation in PD, where patients are grouped using a “mitochondrial risk burden” based on PINK1, Parkin, and a panel of single-nucleotide polymorphisms (SNPs) identified from genome-wide association studies (186).